Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $43.17 Average Target Price from Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received an average rating of “Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $43.17.

Several research analysts recently weighed in on ORKA shares. Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $49.00 price objective on the stock. TD Cowen assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating for the company. Leerink Partners initiated coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research note on Monday, November 25th.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $21.20 on Monday. The firm has a 50 day simple moving average of $25.31. The firm has a market capitalization of $742 million, a price-to-earnings ratio of -3.39 and a beta of 0.78. Oruka Therapeutics has a fifty-two week low of $18.20 and a fifty-two week high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC bought a new position in shares of Oruka Therapeutics during the third quarter worth about $114,763,000. RTW Investments LP bought a new stake in Oruka Therapeutics during the third quarter worth $45,359,000. Franklin Resources Inc. purchased a new position in Oruka Therapeutics in the third quarter valued at about $17,661,000. Braidwell LP purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $12,640,000. Finally, Great Point Partners LLC purchased a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $12,614,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.